ATE466838T1 - Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer - Google Patents

Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer

Info

Publication number
ATE466838T1
ATE466838T1 AT06763311T AT06763311T ATE466838T1 AT E466838 T1 ATE466838 T1 AT E466838T1 AT 06763311 T AT06763311 T AT 06763311T AT 06763311 T AT06763311 T AT 06763311T AT E466838 T1 ATE466838 T1 AT E466838T1
Authority
AT
Austria
Prior art keywords
carnitinine
liver
sulfonamide derivatives
transferase inhibitors
palmitoyl transferase
Prior art date
Application number
AT06763311T
Other languages
English (en)
Inventor
Konrad Bleicher
Simona Maria Ceccarelli
Odile Chomienne
Patrizio Mattei
Tanja Schulz-Gasch
Christoph Martin Stahl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE466838T1 publication Critical patent/ATE466838T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06763311T 2005-06-06 2006-05-29 Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer ATE466838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05104904 2005-06-06
PCT/EP2006/062652 WO2006131452A1 (en) 2005-06-06 2006-05-29 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS

Publications (1)

Publication Number Publication Date
ATE466838T1 true ATE466838T1 (de) 2010-05-15

Family

ID=36940686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763311T ATE466838T1 (de) 2005-06-06 2006-05-29 Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer

Country Status (14)

Country Link
US (4) US7723538B2 (de)
EP (1) EP1891001B1 (de)
JP (1) JP4880678B2 (de)
KR (1) KR100956703B1 (de)
CN (1) CN101189210B (de)
AT (1) ATE466838T1 (de)
AU (1) AU2006256825B2 (de)
BR (1) BRPI0610877A2 (de)
CA (1) CA2608837C (de)
DE (1) DE602006014139D1 (de)
ES (1) ES2342842T3 (de)
IL (1) IL187409A (de)
MX (1) MX2007014927A (de)
WO (1) WO2006131452A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX295245B (es) 2005-06-21 2012-01-26 Mitsui Chemicals Inc Derivado de amida e insecticida que contiene el mismo.
KR20080093123A (ko) 2006-02-13 2008-10-20 에프. 호프만-라 로슈 아게 당뇨병 치료용 헤테로바이사이클릭 설폰아마이드 유도체
US7799933B2 (en) * 2006-12-21 2010-09-21 Hoffman-La Roche Inc. Sulfonamide derivatives
KR100847448B1 (ko) * 2007-03-22 2008-07-21 한국화학연구원 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물
ATE518857T1 (de) * 2007-06-01 2011-08-15 Hoffmann La Roche Piperidin-amidderivate
WO2009002433A1 (en) * 2007-06-22 2008-12-31 Dara Biosciences, Inc. Compositions and methods for treating skin disorders
JP2011525530A (ja) * 2008-06-24 2011-09-22 ダラ・バイオサイエンシズ,インコーポレイテッド 酵素阻害剤およびその使用
PE20130601A1 (es) * 2010-08-03 2013-05-30 Chiesi Farma Spa Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa
RU2578975C2 (ru) * 2010-08-03 2016-03-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP6347451B2 (ja) * 2013-08-02 2018-06-27 国立大学法人富山大学 (ベンゼンスルホニルアミノ)ベンズアミド誘導体およびそれらを有効成分とするship2阻害剤
CN104815154A (zh) * 2015-05-06 2015-08-05 山东宏济堂制药集团有限公司 一种清热润喉糖及其制备方法和应用
WO2021226076A1 (en) * 2020-05-04 2021-11-11 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for detection of bacterial infection
KR102606541B1 (ko) * 2021-04-23 2023-11-29 가천대학교 산학협력단 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000134A1 (en) * 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonists
AU709631B2 (en) * 1996-06-28 1999-09-02 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JP2001526255A (ja) * 1997-12-23 2001-12-18 ワーナー−ランバート・カンパニー 炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
JP2001031652A (ja) * 1998-06-19 2001-02-06 Nissan Chem Ind Ltd 六員環複素環類
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
US20050113450A1 (en) * 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
US20090105218A1 (en) * 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use

Also Published As

Publication number Publication date
AU2006256825B2 (en) 2010-02-18
US20120232104A1 (en) 2012-09-13
IL187409A (en) 2012-03-29
AU2006256825A1 (en) 2006-12-14
US20100144762A1 (en) 2010-06-10
KR20080008401A (ko) 2008-01-23
CN101189210B (zh) 2012-06-06
ES2342842T3 (es) 2010-07-15
WO2006131452A1 (en) 2006-12-14
CA2608837C (en) 2011-08-02
US20060276494A1 (en) 2006-12-07
EP1891001B1 (de) 2010-05-05
BRPI0610877A2 (pt) 2010-08-03
CA2608837A1 (en) 2006-12-14
IL187409A0 (en) 2008-02-09
EP1891001A1 (de) 2008-02-27
JP2008545770A (ja) 2008-12-18
US20110319438A1 (en) 2011-12-29
KR100956703B1 (ko) 2010-05-06
MX2007014927A (es) 2008-02-15
DE602006014139D1 (de) 2010-06-17
US7723538B2 (en) 2010-05-25
JP4880678B2 (ja) 2012-02-22
CN101189210A (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
IL187409A0 (en) Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l- cpt1) inhibitors
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
TW200738655A (en) Novel bicyclic sulfonamide derivatives
TW200745032A (en) Novel heterobicyclic derivatives
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
MY138941A (en) Aryl-pyridine derivatives
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
CR9587A (es) Derivados de piridazina
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
DE602005023015D1 (de) Indolderivate als viruzide
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
MX2010005824A (es) Derivados de aminotiazol.
NO20083390L (no) Piperaziner og piperidiner som mGluR5-forsterkere
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2009003169A (es) Derivados de sulfonamida.
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1891001

Country of ref document: EP